WO2008018789A3 - Methods and means for diagnosing and treatment of osteoarthritis - Google Patents

Methods and means for diagnosing and treatment of osteoarthritis Download PDF

Info

Publication number
WO2008018789A3
WO2008018789A3 PCT/NL2007/050367 NL2007050367W WO2008018789A3 WO 2008018789 A3 WO2008018789 A3 WO 2008018789A3 NL 2007050367 W NL2007050367 W NL 2007050367W WO 2008018789 A3 WO2008018789 A3 WO 2008018789A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoarthritis
subject
diagnosing
treatment
methods
Prior art date
Application number
PCT/NL2007/050367
Other languages
French (fr)
Other versions
WO2008018789A2 (en
Inventor
Eline Petronella Slagboom
Ingrid Meulenbelt
Original Assignee
Univ Leiden Medical Ct
Eline Petronella Slagboom
Ingrid Meulenbelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden Medical Ct, Eline Petronella Slagboom, Ingrid Meulenbelt filed Critical Univ Leiden Medical Ct
Publication of WO2008018789A2 publication Critical patent/WO2008018789A2/en
Publication of WO2008018789A3 publication Critical patent/WO2008018789A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The current invention provides methods for determining the risk of a subject for developing familial generalized osteoarthritis with early or late onset, comprising the step of determining the presence of a genetic marker indicative of a polymorphism affecting function or expression of a gene located on at least one of the human chromosome bands 2q33.2 to 2q34 and 14q24.3 to 14q32.12 in the genome of a subject. The invention also pertains to gene sequences and polymorphisms therein that may be indicative of development of osteoarthritis in a subject.
PCT/NL2007/050367 2006-08-08 2007-07-24 Methods and means for diagnosing and treatment of osteoarthritis WO2008018789A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06118594 2006-08-08
EP06118594.8 2006-08-08

Publications (2)

Publication Number Publication Date
WO2008018789A2 WO2008018789A2 (en) 2008-02-14
WO2008018789A3 true WO2008018789A3 (en) 2008-04-03

Family

ID=37613925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/050367 WO2008018789A2 (en) 2006-08-08 2007-07-24 Methods and means for diagnosing and treatment of osteoarthritis

Country Status (1)

Country Link
WO (1) WO2008018789A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5421374B2 (en) 2008-09-03 2014-02-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Genetic changes of isocitrate dehydrogenase gene and other genes in malignant glioma
CN103045722B (en) * 2012-08-30 2015-03-25 山西省眼科医院 Detection kit of disease-causing gene CRYGD of crystalline congenital cataract
CN110624114B (en) * 2018-06-25 2021-07-16 沈阳何氏眼产业集团有限公司 Application of CRYGD protein
AU2019335401A1 (en) * 2018-09-07 2021-03-11 Regeneron Pharmaceuticals, Inc. Methods and systems for pedigree enrichment and family-based analyses within pedigrees

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047769A1 (en) * 1999-02-15 2000-08-17 Catalyst Biomedica Ltd. Susceptibility locus for osteoarthritis
WO2001018250A2 (en) * 1999-09-10 2001-03-15 Whitehead Institute For Biomedical Research Single nucleotide polymorphisms in genes
WO2002070737A2 (en) * 2001-02-28 2002-09-12 Chondrogene Inc. Compositions and methods relating to osteoarthritis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
US20040067505A1 (en) * 2001-09-26 2004-04-08 Enrique Alvarez Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004035827A2 (en) * 2002-10-18 2004-04-29 Inserm Microarrays allowing molecular profiling of rheumatoid arthritis comparatively to osteoarthritis andtheir use
EP1426056A1 (en) * 2001-09-10 2004-06-09 Takeda Chemical Industries, Ltd. Preventives & remedies for bone & joint diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047769A1 (en) * 1999-02-15 2000-08-17 Catalyst Biomedica Ltd. Susceptibility locus for osteoarthritis
WO2001018250A2 (en) * 1999-09-10 2001-03-15 Whitehead Institute For Biomedical Research Single nucleotide polymorphisms in genes
WO2002070737A2 (en) * 2001-02-28 2002-09-12 Chondrogene Inc. Compositions and methods relating to osteoarthritis
EP1426056A1 (en) * 2001-09-10 2004-06-09 Takeda Chemical Industries, Ltd. Preventives & remedies for bone & joint diseases
US20040067505A1 (en) * 2001-09-26 2004-04-08 Enrique Alvarez Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
WO2004035827A2 (en) * 2002-10-18 2004-04-29 Inserm Microarrays allowing molecular profiling of rheumatoid arthritis comparatively to osteoarthritis andtheir use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE DBSNP [online] 7 August 2001 (2001-08-07), XP002453685, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP/SNP_SS.CGI?SUBSNP_ID=3194845 Database accession no. ss3194845 *
DATABASE DBSNP [online] XP002453686, retrieved from HTTP://WWW.NCBI.NLM.NIH.GOV/SNP/SNP_SS.CGI?SUBSNP_ID=3194846 Database accession no. ss3194846 *
HAGA HISANORI ET AL: "Gene-based SNP discovery as part of the Japanese Millennium Genome Project: Identification of 190562 genetic variations in the human genome.", JOURNAL OF HUMAN GENETICS, vol. 47, no. 11, 2002, pages 605 - 610, ISSN: 1434-5161 *
LOUGHLIN J ET AL: "Linkage analysis of chromosome 2q in osteoarthritis", RHEUMATOLOGY (OXFORD), vol. 39, no. 4, April 2000 (2000-04-01), pages 377 - 381, XP002416190, ISSN: 1462-0324 *
LOUGHLIN J ET AL: "refined linkage mapping of a hip osteoarthritis susceptibility locus on chromosome 2q", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 41, no. 8, August 2002 (2002-08-01), pages 955 - 956, XP002298045, ISSN: 1462-0324 *
MOTOTANI HIDEYUKI ET AL: "A functional single nucleotide polymorphism in the core promoter region of CALM1 is associated with hip osteoarthritis in Japanese", HUMAN MOLECULAR GENETICS, vol. 14, no. 8, April 2005 (2005-04-01), pages 1009 - 1017, XP002453678, ISSN: 0964-6906(print) 1460-2083(ele *
WRIGHT G D ET AL: "Association of two loci on chromosome 2q with nodal osteoarthritis", ANNALS OF THE RHEUMATIC DISEASES, vol. 55, no. 5, 1996, pages 317 - 319, XP000867573, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
WO2008018789A2 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
WO2010019550A3 (en) Method of identifying disease risk factors
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2012024535A3 (en) Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
WO2003012046A3 (en) Stk15 (stk6) gene polymorphism and methods of determining cancer risk
WO2007103808A3 (en) Microrna expression profile associated with pancreatic cancer
WO2008061213A3 (en) Genetic variations associated with tumors
WO2010018601A3 (en) Genetic variants predictive of cancer risk
EP3318643A3 (en) Methods and compositions for identifying and treating lupus
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2008136996A3 (en) Polymorphisms in genes affecting ace-related disorders and uses thereof
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2009097270A3 (en) Method of determining breast cancer risk
WO2008018789A3 (en) Methods and means for diagnosing and treatment of osteoarthritis
WO2006110748A3 (en) Response gene to complement 32 (rgc-32) in disease
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
EP3075865A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
WO2008070325A3 (en) Genetic variations associated with tumors
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
WO2006053955A3 (en) Method and kit for detecting a risk of essential arterial hypertension
WO2004035819A8 (en) Oligonucleotide analogues for detecting and analyzing nucleic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07793868

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07793868

Country of ref document: EP

Kind code of ref document: A2